Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OK Biotech CoTPE:4155 67 EV-to-EBITDA is 11.42 as of Aug. 17, 2026, which is 20% below its 10-year median of 14.27. GuruFocus rates TPE:4155 with a GF Score™ of 67/100 and a GF Value™ of NT$23.92 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 513 Medical Devices & Instruments companies, OK Biotech Co ranks better than 62.96% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, OK Biotech Co's enterprise value is NT$2,780 Mil.
OK Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was NT$243 Mil. Therefore, OK Biotech Co's EV-to-EBITDA for today is 11.42.
The historical rank and industry rank for OK Biotech Co's EV-to-EBITDA or its related term are showing as below:
TPE:4155'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.09 Med: 14.27 Max: 45.71
Current: 11.42
During the past 13 years, the highest EV-to-EBITDA of OK Biotech Co was 45.71. The lowest was 8.09. And the median was 14.27.
TPE:4155's EV-to-EBITDA is ranked better than 62.96% of 513
companies
in the Medical Devices & Instruments industry
Industry Median: 14.95
vs TPE:4155: 11.42
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
OK Biotech Co's PE Ratio (TTM) for today is calculated as:
OK Biotech Co's share price for today is NT$14.80.
OK Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.780.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for OK Biotech Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4155 vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, OK Biotech Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OK Biotech Co EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OK Biotech Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where OK Biotech Co's EV-to-EBITDA falls into.
OK Biotech Co's current Enterprise Value is NT$2,780 Mil.
OK Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$243 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OK Biotech Co (TPE:4155) has a EV-to-EBITDA of 11.42 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on OK Biotech Co. This is 20% below median its historical median of 14.27. Over the past decade, OK Biotech Co's EV-to-EBITDA has ranged from 8.09 to 45.71. According to the industry distribution chart, OK Biotech Co ranks #190 out of 513 companies in the Medical Devices & Instruments industry, placing it in the top 37%.
Is OK Biotech Co's EV-to-EBITDA too high?
OK Biotech Co's current EV-to-EBITDA of 11.42 is 20% below median its 10-year median of 14.27. Over the past 10 years, this metric has ranged from a low of 8.09 to a high of 45.71. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.95. OK Biotech Co's value of 11.42 is 23.6% below this industry median. Based on the distribution chart, OK Biotech Co ranks #190 out of 513 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, OK Biotech Co has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OK Biotech Co's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OK Biotech Co ranks #190 out of 513 companies for EV-to-EBITDA. This puts OK Biotech Co in the upper half of its industry. The industry median EV-to-EBITDA is 14.95. OK Biotech Co's value of 11.42 is 23.6% below this benchmark. Historically, OK Biotech Co's own EV-to-EBITDA has ranged from 8.09 to 45.71 over the past decade. While the company's 10-year median is 14.27 vs. the industry median of 14.95, OK Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.95, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OK Biotech Co's current EV-to-EBITDA of 11.42 is 23.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on OK Biotech Co. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OK Biotech Co's current EV-to-EBITDA is 11.42, which is 20% below median its own 10-year median of 14.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OK Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, OK Biotech Co (TPE:4155) is currently considered Possible Value Trap. The stock's GF Value™ is NT$23.92, compared to a current price of NT$14.80 — trading 38.1% below its estimated fair value. The current EV-to-EBITDA is 11.42, which is 20% below median its 10-year median of 14.27 and 23.6% below the Medical Devices & Instruments industry median of 14.95. OK Biotech Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For OK Biotech Co (TPE:4155), the current EV-to-EBITDA is 11.42 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OK Biotech Co (TPE:4155) Overvalued in 2026?
Based on GuruFocus' analysis, OK Biotech Co stock appears to be undervalued.
The current stock price of NT$14.80 is trading 38.1% below its estimated GF Value™ of NT$23.92.
GuruFocus considers OK Biotech Co to be Possible Value Trap.
Key valuation signals for TPE:4155:
EV-to-EBITDA: 11.42 (20% below median its 10-year median of 14.27)
GF Value™: NT$23.92 vs. price of NT$14.80 (38.1% below fair value)
Industry Position: 23.6% below the Medical Devices & Instruments median (#190 of 513)
No single metric tells the full story. See the TPE:4155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OK Biotech Co Ltd is mainly engaged in the manufacturing, wholesale, and retail of electronic materials and medical equipment. Its product portfolio comprises blood glucose monitoring systems, OTC hearing aids, multi-frequency therapy devices, and others. Geographically, the company generates the majority of its revenue from America, and the rest from Asia (excluding Taiwan), Africa, Europe, and Taiwan.
67GF Score
Get the complete analysis for TPE:4155
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4155 has been successfully added to your 
